secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001493152-25-010981
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Therapeutics reports FY2024 net loss $63.7M, cash $98.1M, pz-cel PDUFA April 29
--------------------------------------------------------------------------------

- Net loss of $63.7M ($1.55 per share) for FY2024 vs $54.2M ($2.53 per share) in FY2023.
- Cash and investments total $98.1M as of Dec 31, 2024, up from $52.6M; runway into 2026.
- FDA PDUFA target action date for pz-cel BLA is April 29, 2025; draft label received March 14.
- If approved, first patient treatment with pz-cel expected in Q3 2025; launch prep with five QTCs underway.
- Two additional patents for pz-cel extend protection to June 2037 and July 2040.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315225010981/0001493152-25-010981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315225010981/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-010981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer